August 11, 2026 08:10 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Jharkhand student protest turns tense: Water cannons, lathicharge after Assembly march barricades breached | ‘Mother tongue is as pure as one's mother’: Vijay-led Tamil Nadu government makes Tamil Thaai Vazhthu mandatory in big language push | Indian envoy Kwatra cites US, UK laws to counter ‘myths’ around FCRA Bill | Jharkhand students march to assembly today: JPSC row escalates despite govt action | ‘A morning I will cherish’: Raghav Chadha meets PM Modi, shares photos from ‘enriching’ meeting | Delhi Mercedes crash kills 70-year-old woman: Cop’s son behind wheel, beer bottle found | Indian-origin woman accused of ‘visa fraud’ on X: US Attorney steps in with major clarification | US Senate passes Russia sanctions bill: India can face Trump’s 100% tariff threat | Expired meat, rotten vegetables found at Bengaluru's luxury hotels, legal action begins | 'I'm ready to be humiliated': Vijay, Udhayanidhi Stalin clash in Tamil Nadu Assembly over Cauvery dispute
Johnson & Johnson
Pixabay

Fight against COVID-19: Johnson & Johnson's vaccine shows strong immune response

| @indiablooms | Sep 26, 2020, at 02:21 pm

New Brunswick: US pharmaceutical major  Johnson & Johnson's potential COVID-19 vaccine has shown development of a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated.

The company published an interim analysis from the ongoing Phase 1/2a clinical trial of the Janssen COVID-19 vaccine candidate (JNJ-78436735) on Friday.

" Immune responses were similar across the age groups studied, including older adults," the company said in a statement.

"The ongoing Phase 1/2a clinical trial is designed to study the safety and immunogenicity of two dose levels of the Janssen COVID-19 vaccine, and as single and two-dose schedules," the company said.

The interim analysis showed that a single dose induced a robust immune response and was generally well-tolerated.  

" These data are consistent with preclinical studies, published in the scientific journal Nature, which showed that a single dose of the vaccine successfully prevented subsequent infection and provided complete protection in the lungs of nonhuman primates," read the statement.

"Based on these findings, the single dose of the Janssen COVID-19 vaccine candidate of 5x1010 virus particles (vp) has been selected for further evaluation in the Phase 3 ENSEMBLE clinical trial," the company said.

The company also plans on running a Phase 3 clinical trial of a two-dose regimen of JNJ-78436735 versus placebo later this year.

The full set of results will be published once the complete Phase 1/2a trial data are available.
" The Janssen COVID-19 vaccine candidate elicited strong antibody responses, strong T cell responses, and a Th1 response, believed to be protective against the risk of vaccine-associated enhanced respiratory disease," the company said.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.